Response of Children With Atopic Dermatitis (Eczema) to Eucrisa

• Status: Recruiting
• Trial end date: 2021-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to develop biomarkers to predict what medication is best for each child with atopic dermatitis (eczema). Participants will come in to Lurie Children's Allergy of Dermatology clinic for a skin examination and complete surveys. They will apply Eucrisa medication to their skin for 28 days before returning for a second and final skin examination and complete surveys. During these skin exams, tape will be placed on the skin and removed to collect skin cell samples. Photos will also be taken of the skin where tape was placed. There is an optional blood draw.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago
• Collaborator: Pfizer

Criteria

Inclusion Criteria:

• AD diagnosis by dermatologist or allergist based on Hanifin and Rajka criteria

• 5% or more treatable body surface area involvement

• baseline Investigator's Static Assessment (ISGA) score of mild (2) or moderate (3)

• patient on stable regimens (consistent use 14 days before day 1 of enrollment) of inhaled corticosteroids and antihistamines

• must have lesional skin in the antecubital fossa

Exclusion Criteria:

• use of topical corticosteroid, calcineurin inhibitor, or PDE4 inhibitor within 14 days of enrollment

• significant active infection

• any previous use of biologic therapy

• no pruritus at baseline visit, or other pruritic condition

• washing/moisturizer use 24 hours prior to tape strip biomarker collection at site

• uncontrolled asthma, uncontrolled allergic rhinitis, or other sleep disturbing condition